6586.TWO CHO Pharma Inc.
- Market cap
- TWD 16.4B
- P/E
- -
- P/B
- 8.14x
- ROE
- -11.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6586.TWO undervalued?
Graham numberThe Graham number of CHO Pharma Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CHO Pharma Inc. fundamental analysis
No fundamental analysis for CHO Pharma Inc. yet.
CHO Pharma Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CHO Pharma Inc.
CHO Pharma, Inc., engages in research and development of biotechnology in Taiwan. It develops glycoengineering platform technologies, including SAR-based glycoengineered biobetters; glycosite-specific antibody-drug conjugates (ADCs); novel antibodies and vaccines targeting novel carbohydrate antigens; and programs using its glycoengineering technologies. The company also provides CHOptimax, an in vitro enzymatic one-pot process that converts naked antibodies into glycoengine…
Full company profileCHO Pharma Inc. financial statements
CHO Pharma Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 297K | 138K | 3.57M | 60.0K | 0.00 | 3.58M | 1.43M |
| Gross Profit | 178K | 67.0K | 3.36M | 59.0K | 0.00 | 1.71M | 1.07M |
| Operating Income | -369M | -296M | -205M | -338M | -306M | -249M | -326M |
| EBITDA | -340M | -255M | -166M | -298M | -278M | -186M | -263M |
| Net Income | -358M | -297M | -206M | -338M | -306M | -212M | -290M |
| EPS | -1.96 | -1.62 | -1.12 | -1.84 | -1.60 | -0.99 | -1.36 |
| Balance Sheet | |||||||
| Total Assets | 2.43B | 2.14B | 1.89B | 1.60B | 3.09B | 2.88B | 2.57B |
| Total Liabilities | 29.0M | 180M | 150M | 174M | 111M | 133M | 109M |
| Shareholders' Equity | 2.26B | 1.96B | 1.74B | 1.43B | 2.98B | 2.75B | 2.46B |
| Cash & Short-term Investments | 1.80B | 1.53B | 1.32B | 1.04B | 2.60B | 21.8M | 52.1M |
| Total Debt | 29.0M | 38.3M | 25.6M | 11.7M | - | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | -267M | -249M | -193M | -250M | -291M | -217M | -280M |
| Capital Expenditure | 11.4M | 22.2M | 2.64M | 9.40M | 2.00M | 5.49M | 11.7M |
| Free Cash Flow | -278M | -271M | -196M | -259M | -293M | -223M | -291M |
| Ratios | |||||||
| ROE | -15.8% | -15.1% | -11.8% | -23.7% | -10.3% | -7.7% | -11.8% |
| ROA | -14.8% | -13.9% | -10.9% | -21.1% | -9.9% | -7.4% | -11.3% |
| Net Profit Margin | -120,664.0% | -215,100.7% | -5,768.2% | -563,988.3% | - | -5,928.1% | -20,266.0% |
| Debt to Equity | 0.01x | 0.02x | 0.01x | 0.01x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CHO Pharma Inc. dividends
CHO Pharma Inc. has not paid dividends in the last 7 fiscal years.
Who owns CHO Pharma Inc.
- Insiders 0.00%
- Institutions 0.02%
- Public & others 99.98%
- Shares outstanding 214M
- Free float 144M
CHO Pharma Inc. company profile
- Company name
- CHO Pharma Inc.
- Ticker
- 6586.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- Building C, Taipei, Taiwan, 115202
- Phone
- 886 2 2655 8059
- Website
- chopharma.com
About CHO Pharma Inc.
CHO Pharma, Inc., engages in research and development of biotechnology in Taiwan. It develops glycoengineering platform technologies, including SAR-based glycoengineered biobetters; glycosite-specific antibody-drug conjugates (ADCs); novel antibodies and vaccines targeting novel carbohydrate antigens; and programs using its glycoengineering technologies. The company also provides CHOptimax, an in vitro enzymatic one-pot process that converts naked antibodies into glycoengineered biobetter or ADC. In addition, the company develops CHO-H01, which is in Phase I/IIa clinical trials for the treatment of refractory non-Hodgkin lymphoma; CHO-A04, a humanized monoclonal antibody, which is in phase I clinical trials to treat various tumor and cancer stem cells; and CHO-V08 vaccines for the treatment of klebsiella pneumonia. Further, it develops CHO-H02 that is in preclinical stage to target solid tumors, including breast, bladder, pancreatic, ovarian, and gastric cancers; and CHO-H03, an antibody drug that is in pre-clinical development stage indicated for inflammatory conditions in autoimmune diseases such as rheumatoid arthritis, ulcerative colitis and Crohn's disease. CHO Pharma, Inc. was founded in 2012 and is based in Taipei City, Taiwan.
CHO Pharma Inc. management
4- Dr. Chung-Yi Wu Ph.D.President, CEO, GM & Director
- Mr. Wen-Huang TsaiChief Financial Officer
- Dr. Ling-Mei WangVice President of Operation
- Yibei ZhouAccounting Supervisor